NIKKEI 225
39,121.07 +316.42 (+0.82%) HANG SENG
18,139.75 +112.04 (+0.62%) CRUDE OIL
81.72 +0.09 (+0.11%) GOLD FUTURES
2,339.70 -4.70 (-0.20%) DOW
39,411.21 +260.88 (+0.67%) Bitcoin GBP
48,045.40 -1,020.91 (-2.08%)
MLYS Jun 2024 5.000 call
| Previous close | 8.40 |
| Open | 4.20 |
| Bid | 6.90 |
| Ask | 10.50 |
| Strike | 5.00 |
| Expiry date | 2024-06-21 |
| Day's range | 4.20 - 8.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GuruFocus.comInsider Sale: CEO Jon Congleton Sells Shares of Mineralys Therapeutics Inc (MLYS)
On June 20, 2024, Jon Congleton, CEO of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a significant transaction by selling 49,313 shares of the company. Following this sale, the insider now owns 926,958 shares of Mineralys Therapeutics Inc. Mineralys Therapeutics Inc is focused on developing targeted therapies for cardiovascular and kidney diseases.
GuruFocus.comMineralys Therapeutics Inc (MLYS) CEO Jon Congleton Sells 72,797 Shares
On June 14, 2024, Jon Congleton, CEO of Mineralys Therapeutics Inc (NASDAQ:MLYS), executed a sale of 72,797 shares of the company, according to the SEC Filing.
GlobeNewswireMineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
Dr. Olivier Litzka has resigned from the Board, effective June 13, 2024RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that Alexander M. Gold, M.D. has been appointed to the Company's Board of Directors (the Board), effective June 13, 2024. “We are delighte
